LYRA
Lyra Therapeutics, Inc.Company with tickers: LYRA
CIK
1327273
CUSIP
55234L204
Shares Outstanding
1,774,882
Website
https://www.lyratx.com
13F Activity (30d)
2 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $398,000 | USD | 2025-12-31 | 10-K | 2026-03-31 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $31,420,000 | USD | 2025-12-31 | 10-K | 2026-03-31 |
| Research & Development | $18,411,000 | USD | 2025-12-31 | 10-K | 2026-03-31 |
| Operating Income | $-31,022,000 | USD | 2025-12-31 | 10-K | 2026-03-31 |
| Net Income | $-28,919,000 | USD | 2025-12-31 | 10-K | 2026-03-31 |
| EPS (Basic) | $-18.62 | USD/shares | 2025-12-31 | 10-K | 2026-03-31 |
| EPS (Diluted) | $-18.62 | USD/shares | 2025-12-31 | 10-K | 2026-03-31 |